Venlafaxine Extended-Release Capsules
Healthy Inc is a specialized global supplier and exporter of advanced central nervous system (CNS) and psychiatric therapeutics. We provide high-purity Venlafaxine Extended-Release Capsules (37.5 mg / 75 mg / 150 mg), manufactured in WHO–GMP certified advanced pelletization facilities. This “Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)” is a highly strategic, large-volume export to psychiatric hospitals, behavioral health clinics, and government health ministries in Africa, LATAM, and Southeast Asia, serving as a highly effective, dose-adjustable intervention for Major Depressive Disorder (MDD) and severe, treatment-resistant anxiety disorders.
Product Overview
This formulation contains Venlafaxine (as Venlafaxine Hydrochloride), a structurally unique bicyclic antidepressant that acts as a potent SNRI.
The “Dose-Dependent Neuro-Modulator” Specialist:
- Mechanism (Sequential Reuptake Blockade): Venlafaxine powerfully inhibits the reuptake of key neurotransmitters, but does so sequentially based on the dose. At lower doses (e.g., 37.5 mg to 75 mg), it acts almost exclusively as a Serotonin Reuptake Inhibitor (SSRI). As the dose is titrated upward (150 mg to 225 mg), it begins to heavily inhibit the Norepinephrine Transporter (NET). At extremely high doses, it also weakly inhibits dopamine reuptake.
- The “Activating” Advantage: Because of its strong noradrenergic push at standard therapeutic doses, Venlafaxine is incredibly effective for patients suffering from melancholic depression, severe psychomotor retardation, and chronic fatigue, providing an “activating” or energizing effect that standard SSRIs often fail to deliver.
- Extended-Release Necessity: The base molecule has an exceptionally short half-life (around 5 hours). To prevent severe inter-dose withdrawal and intolerable nausea, our formulation traps the API inside specialized polymer-coated spheroids. This delivers a smooth, steady-state plasma concentration over 24 hours.
Product Composition & Strength
We supply this product as a Hard Gelatin Capsule containing Sustained-Release (SR) Pellets, packed in moisture-resistant Alu-Alu or heavy-gauge Alu-PVC blister strips.
| Active Ingredient | Strength (Base Equivalent) | Primary Clinical Use |
|---|---|---|
| Venlafaxine Hydrochloride USP/BP | 37.5 mg (SR Pellets) | Initiation Dose (To mitigate initial nausea) / Tapering |
| Venlafaxine Hydrochloride USP/BP | 75 mg (SR Pellets) | Standard Starting/Maintenance Dose for MDD & GAD |
| Venlafaxine Hydrochloride USP/BP | 150 mg (SR Pellets) | Target Maintenance Dose for Severe Depression & Panic Disorder |
| Excipients | Ethylcellulose / Hypromellose / Sugar Spheres | Rate-Controlling Polymers / Pellet Core |
*Pack Sizes: 10×10 Alu-Alu Blisters or 10×14 Blisters (Optimized for 14-day psychiatric titration schedules).
Technical & Logistics Specifications
Critical data for Pharmaceutical Importers and Distributors.
| HS Code | 3004.90.99 (Medicaments containing other active substances) |
| CAS Number | 99300-78-4 (Venlafaxine Hydrochloride) |
| Dosage Form | Capsules containing Extended-Release Pellets |
| Packaging | Alu-Alu or High-Barrier Alu-PVC Blisters. |
| Storage | Store below 25°C in a dry place. Protect strictly from Light and Moisture. |
| Certificates | WHO-GMP, COPP, Free Sale Certificate |
Manufacturing Authority
Marketed and Distributed by Healthy Inc from WHO-GMP & ISO 9001:2015 certified units.
- Precision Polymer Diffusion: Our fluid-bed manufacturing technology coats the active Venlafaxine onto spherical cores, followed by a highly calibrated, semi-permeable ethylcellulose membrane. Fluid in the GI tract penetrates this membrane, dissolving the drug and allowing it to diffuse out at a mathematically controlled rate over 24 hours, completely eliminating the risk of sudden “dose dumping.”
- Hygroscopic Control: Encapsulation is performed under strictly climate-controlled conditions (RH <40%) to prevent the hydrophilic polymer matrix from swelling prematurely prior to ingestion.
Therapeutic Indications (Human Use)
Indicated for the comprehensive management of psychiatric and anxiety disorders:
- Major Depressive Disorder (MDD): Acute and maintenance treatment of severe clinical depression.
- Generalized Anxiety Disorder (GAD): Long-term management of excessive, uncontrollable worry.
- Social Anxiety Disorder (SAD): Treatment of severe, debilitating social phobias.
- Panic Disorder: Treatment of panic attacks, with or without agoraphobia.
Dosage & Administration
Recommended Dosage (Strictly as per Psychiatrist):
- Administration: Taken orally once daily, with food (to further minimize gastrointestinal irritation and nausea), at roughly the same time each day (usually morning due to its activating effects).
- MDD & GAD (Adults): Typically initiated at 75 mg/day (or 37.5 mg/day for 4 to 7 days in sensitive patients to reduce nausea before increasing to 75 mg). Can be titrated upwards in increments of 37.5 mg or 75 mg to a maximum of 225 mg/day.
- Swallowing Protocol (CRITICAL): The capsule must be swallowed whole with a fluid. DO NOT CRUSH, CHEW, OR DISSOLVE THE CAPSULE OR ITS PELLETS. However, if a patient cannot swallow capsules, the capsule may be carefully opened and the entire contents sprinkled on a spoonful of applesauce and swallowed immediately without chewing.
Safety Warnings (CRITICAL):
- BLACK BOX WARNING (Suicidality): Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (up to age 24). Close clinical monitoring is mandatory.
- Severe Discontinuation Syndrome: Abrupt cessation or even missing a single dose can cause intense, highly distressing withdrawal symptoms, notoriously including sensory disturbances (“brain zaps” or electrical shock sensations), severe dizziness, and extreme nausea. Therapy MUST be tapered very slowly over weeks or months.
- Sustained Hypertension: Because it increases norepinephrine, Venlafaxine can cause dose-dependent, sustained increases in blood pressure. Blood pressure must be monitored regularly during treatment.
- Serotonin Syndrome: Risk of potentially life-threatening serotonin syndrome when co-administered with other serotonergic agents (e.g., MAOIs, Triptans, Tramadol).
Global Export & Contract Manufacturing Services
Healthy Inc stands as a premier Pharmaceutical Exporter in India, dedicated to serving the needs of international Pharma Traders, Wholesalers, and Bulk Drug Distributors. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) services for CNS and Psychiatric Medicines, allowing brands to launch high-quality generic medicines under their own label. Whether you are looking for a reliable Hospital Tender Supplier for government procurement in Africa or a B2B Pharma Marketplace partner for Latin America, our logistics network ensures timely delivery. We actively support Pharmaceutical Drop Shipping models and bulk indenting, ensuring that every Generic Medicine Wholesaler receives WHO-GMP certified products at competitive rates.